Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Queen Mary University Of London
Sponsor

Queen Mary University Of London

United Kingdom 327 Mile End Road, E1 4NS, United Kingdom

About the sponsor

Clinical research in urothelial carcinoma spans tumours of the bladder and upper urinary tract, with attention to disease that requires surgery and to rare histological subtypes. The studies also examine neoadjuvant immunotherapy and immune checkpoint inhibition in relation to tumour shrinkage and immune activity.

  • Neoadjuvant immune checkpoint inhibitors
  • Pathological complete response
  • Upper urinary tract malignancy
  • Rare histological subtypes

Research activity in this area also includes maintenance avelumab and treatment strategies for advanced urothelial cancer.

About Specializations

Queen Mary University Of London runs clinical trials in conditions such as Triple negative breast cancer, Rheumatoid arthritis, Transitional cell carcinoma, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

6 clinical trials

Triple negative breast cancer

Recruiting

A study comparing datopotamab deruxtecan with durvalumab versus datopotamab deruxtecan alone for patients with PDL1-negative metastatic triple-negative breast cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Durvalumab
  • Sponsor:Queen Mary University Of London

Rheumatoid arthritis

Recruiting

Study on Abatacept for Predicting Treatment Response in Patients with Early Rheumatoid Arthritis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abatacept
  • Sponsor:Queen Mary University Of London

Rheumatoid arthritis

Recruiting

Study on Sarilumab and Etanercept for Rheumatoid Arthritis in Patients Not Responding to csDMARD Therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Etanercept
  • Sponsor:Queen Mary University Of London

Triple negative breast cancer

Not yet recruiting

Study of ipatasertib with atezolizumab and chemotherapy in women with triple-negative breast cancer before surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Queen Mary University Of London

Transitional cell carcinoma

Not recruiting

Study on the Effects of 3 vs 6 Cycles of Platinum-based Chemotherapy and Avelumab in Patients with Advanced Urothelial Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Queen Mary University Of London

Transitional cell carcinoma

Not recruiting

Study of Atezolizumab Treatment Before Surgery in Patients with Bladder Cancer or Upper Urinary Tract Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Queen Mary University Of London

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.